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Translational relevance 
Neuroblastoma is a childhood malignancy originating from the sympathetic nervous system that 
is prone to metastasize and relapse. PML is a tumour suppressor gene frequently deregulated 
in cancer, but its prognostic and functional significance in neuroblastoma is unknown. A fraction 
of localized neuroblastomas recur locally after surgery and can do so several times in spite of 
further treatments, eventually killing the patient. In this study we have established that PML-I is 
a negative regulator of angiogenesis via activation of thrombospondin-2 and its reduced or 
absent expression in localized neuroblastoma is an accurate marker of the risk of relapse. An 
important clinical implication of our study is that PML expression could be now used to identify 
patients with low-risk, localized tumors needing systemic treatments to avoid cancer recurrence. 
 
Abstract 
 
Purpose. Neuroblastoma is a childhood malignancy originating from the sympathetic nervous 
system with a complex biology, prone to metastasize and relapse. High-risk, metastatic cases 
are explained in part by amplification or mutation of oncogenes such as MYCN and ALK and 
loss of tumour suppressor genes in chromosome band 1p. However, it is fundamental to identify 
other pathways responsible for the large portion of neuroblastomas with no obvious molecular 
alterations.  
Experimental design. Neuroblastoma cell lines were used for assessment of tumour growth in 
vivo and in vitro. Protein expression in tissues and cells was assessed using 
immunofluorescence and immunohistochemistry. The association of PML expression with 
neuroblastoma outcome and relapse was calculated using log-rank and Mann-Whitney tests, 
respectively. Gene expression was assessed using chip microarrays.  
Results: PML is detected in the developing and adult sympathetic nervous system, whereas it 
is not expressed or low in metastatic neuroblastoma tumours. Reduced PML expression in 
patients with low-risk cancers - i.e. localized and negative for the MYCN protooncogene - is 
strongly associated with tumour recurrence. PML-I, but not PML-IV, isoform suppresses 
angiogenesis via upregulation of thrombospondin-2 (TSP-2), a key inhibitor of angiogenesis. 
Finally, PML-I and TSP-2 expression inversely correlates with tumour angiogenesis and 
recurrence in localized neuroblastomas. 
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Conclusions: Our work reveals a novel PML-I-TSP2 axis for regulation of angiogenesis and 
cancer relapse, which could be used to identify patients with low-risk, localized tumours that 
might benefit from chemotherapy. 
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Introduction 
The Promyelocytic Leukaemia protein (PML) is a growth/tumour suppressor inactivated in Acute 
Promyelocytic Leukaemia (APL) via the t(15;17) translocation. PML is expressed as multiple 
splice variants and is the essential component of a subnuclear structure called the PML nuclear 
body (PML-NB), which is disrupted in APL (1). PML has emerged as pleiotropic growth 
suppressor affecting multiple cellular pathways involved in tumourigenesis, in part via 
recruitment of nuclear factors to the PML-NBs, also required for activation of p53 (2-8). One of 
the main physiological roles of PML is its ability to regulate cell fate in stem/progenitor cells in 
multiple tissues (9). In the nervous system, we have shown that PML regulates neurogenesis 
and cortex development by modifying the Retinoblastoma (pRb) G1/S checkpoint (9, 10). Most 
growth and tumour suppressive activities of PML have been linked to the splice variant PML-IV 
(11), whereas little is known about the other more abundant variants, such as PML-I (12, 13). 
PML expression is lost in tumours of multiple histological origins, and its inactivation has been 
shown to promote tumour progression in APL, prostate and lung cancer (5, 14-16). In contrast, it 
may play an oncogenic role in chronic myeloid leukaemia and breast cancer (17, 18). PML role 
in tumours of the nervous system has not been investigated. 
Neuroblastoma is the most common extra-cranial solid tumour in childhood and the most 
frequently diagnosed malignancy in infancy. It accounts for 8% of cancer cases in children and 
approximately 15% of all childhood cancer deaths, highlighting the aggressive nature of this 
tumour (19, 20). The tumour develops from neural crest-derived sympathoadrenal precursor 
cells (20). Neuroblastoma is characterized by a number of genetic aberrations; these include 
ploidy changes, gains of chromosome arm 17q, amplification of the proto-oncogene MYCN, 
activating mutations of ALK, and deletions of different genomic regions containing putative 
tumour suppressor genes in chromosome bands 11q23, 1p36 and 14q23-qter(19, 21-24). 
Neuroblastomas commonly arise from the medullary region of the adrenal gland (20, 25) and 
are classified into five stages (1-4 and 4S), according to the International Neuroblastoma 
Staging System (INSS) (26, 27).  Low-risk patients (stages 1, 2 and 4S with a favourable 
histology) have a survival rate greater than 85% whereas the survival rate for high-risk 
neuroblastoma (stages 3,4 with unfavourable histology and MYCN amplification) is less than 
50% in spite of multimodal therapy, reflecting the propensity of the tumour to relapse into a 
treatment resistant, fatal form of the disease (20, 27, 28). Recurrent neuroblastoma in patients 
initially classified as low-risk is uncommon, but can develop into an intractable cancer. It would 
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be very important to identify patients at risk of recurrence needing chemotherapy in addition to 
surgical removal of the localized tumour mass. 
In this study, we show that PML expression inversely correlates with tumour relapse in localized 
neuroblastomas and is lost in aggressive forms of human and mouse neuroblastomas. The 
PML-I isoform, when overexpressed in neuroblastoma cells, does not affect proliferation or 
survival, but instead it suppresses angiogenesis in vitro and in vivo. Mechanistically, PML-I 
inhibits angiogenesis by upregulating Thrombospondin-2, a known angiogenesis suppressor. 
Finally, PML-I expression inversely correlates with tumour angiogenesis in primary tumour 
samples. Overall, these data implicate PML in isoform-specific regulation of neuroblastoma 
pathogenesis and suggest that it may serve as predictor of relapse in localized neuroblastoma.  
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Materials and Methods 
Cell culture. IMR32, SH-EP, SK-N-SH, SK-N-AS, Kelly, NB69 and LAN-5 human 
neuroblastoma lines were a kind gift from Dr Louis Chesler’s lab (Institute of Cancer Research, 
London, UK). SHSY5Y human neuroblastoma cell line was purchased from ATCC. The cells 
were cultured in DMEM- or RPMI-based media supplemented with 10% foetal calf serum, 2 mM 
L-glutamine, 100 mg/mL penicillin and 100 mg/mL streptomycin. Cell lines were sent to Public 
Health England or DDC Medical for authentication. The validation method used was Short 
Tandem Repeat (STR) assay. For ex vivo mouse neural crest trunk progenitor cultures, the 
neural tubes were dissected from e9.5 C57BL/6 mouse embryos, and the trunk section of the 
tube was placed on laminin/fibronectin-covered coverslip and left to attach in a drop of 
dissection medium (DMEM:F-12 medium 1:1 +5%FCS+100 mg/mL penicillin+100 mg/mL 
streptomycin). The explants were cultured for 24-48 hours in neural tube culture medium 
(DMEM/F12 1:1 supplemented with N2, B27 (both Invitrogen), bFGF 20ng/ml and EGF 20ng/ml. 
The coverslips with the neural tube explants and migrated progenitors were fixed in 4% PFA 
and used for immunostaining. 
Cell proliferation assessment. Cells were plated in 12-well plates and cultured until fully 
confluent. During the culturing period, images were acquired at regular intervals using IncuCyte 
live-cell imaging system (Essen Biosciences) and processed using the IncuCyte software to 
calculate the growth rates. 
Patients and Clinical Follow-up. A retrospective series of primary tumours from 
neuroblastoma (NB) patients (Table 1, Supplementary Tables 1 and 2) was collected at the 
Istituto Giannina Gaslini, Genova, Italy (January 2000 to December 2008) and Great Ormond 
Street Hospital (GOSH)/UCL Institute of Child Health (until 2013). All patients included in the 
Gaslini cohort received surgical treatment, and the only inclusion criterion was the availability of 
the complete clinical records. The study was approved by the respective Institutional Review 
Boards and informed consent was obtained from patients or their legal guardians at both 
institutions. Patients were classified according to the International Neuroblastoma Staging 
System classification (29). Event-Free Survival (EFS) was calculated from diagnosis to last 
follow-up or event (first occurrence of relapse, progression, or death). 
Tumour Specimens. Formalin-fixed, paraffin-embedded tissue sections from NB tumours were 
studied. Each tumour area tested contained malignant cells, as assessed by histological 
examination. Quantification of immunofluorescence- or DAB-positive tumour cells was 
performed on serial tumour tissue sections, thus allowing quantification in tumour areas 
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selected by the pathologist. Tumour cells were distinguished in the samples using NB-specific 
marker NCAM (NB56). The adhesion molecule NCAM has been shown to be widely and brightly 
expressed on NB tumours (30). All tumours were evaluated at the time of diagnosis prior to any 
treatment other than surgery. 
Immunostaining of cultured cells. For immunostaining of human or mouse cells in culture, 
cells were grown on poly-D-lysine coated coverslips and fixed with 4% PFA. Tissue sections or 
cells were permeabilised with 0.5% Triton-X100, subjected to antigen retrieval (tissue sections 
only), blocked using 10% normal goat serum/2.5%BSA/0.1% PBS-Tween and incubated with a 
primary antibody diluted in blocking solution overnight at 4°C, followed by incubation with a 
secondary antibody (AlexaFluor, Invitrogen) in blocking solution for 1 hour at room temperature, 
counterstained with Hoechst and mounted for microscopy. 
Immunofluorescence analysis and quantifications of micro-vessel density in tissue 
samples. Mouse tissue samples were fixed in 4% PFA, dehydrated and embedded in paraffin 
or preserved by snap-freezing in liquid N2. Tissue sections were cut and mounted on glass 
slides. Paraffin-embedded sections were deparaffinised and rehydrated. Frozen sections were 
fixed in 4% PFA or cold acetone (specific for CD31 staining). Standard histochemical protocol 
was used for haematoxylin and eosin staining. Indirect immunofluorescence was performed on 
formalin-fixed, paraffin embedded tissues from 30 primary NB tumours as previously described 
(31). Paraffin sections (4 μm thick) were processed by standard deparaffinisation with xylene 
and hydrated in a descending ethanol series to double-distilled water. Antigen retrieval on 
formalin-fixed tissue section was performed using Sodium-Citrate buffer (pH 6.0). Slides were 
incubated with primary antibodies overnight at 4°C. Secondary antibodies used were: goat anti-
mouse IgG Alexa-488, goat anti-rabbit IgG Alexa-568 (diluted 1:200; Invitrogen, Germany), 
donkey anti-goat IgG-NL557 (diluted 1:200; R&D Systems, Inc, Europe). After washing, the 
slides were counterstained with 4’,6’-diamidino-2- phenylindole (DAPI, Sigma-Aldrich, Milan, 
Italy) and cover-slipped. The proportion of immunofluorescence positive tumour cells counted 
was at least 100-1000 cells and reported in the percentage for the subsequent statistical 
analysis. The micro-vessel count (MVC) was assessed by anti-CD31 staining and examination 
of twenty microscopic fields (0.5 mm2) per tumour. The most intense vascular areas (hotspots) 
were selected subjectively from each tumour section. The micro-vessels with a clearly defined 
lumen or well-defined linear vessel shape were taken into account for MVC. 
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Digital images were collected using a Nikon E-1000 fluorescence microscope (Nikon 
Instruments, Tokyo, Japan) equipped with appropriate filter sets and the Genikon imaging 
system software (Nikon Instruments). 
Western blotting. Cells were lysed in Laemmli buffer supplemented with β-mercaptoethanol. 
The proteins were resolved on SDS-PAGE and transferred onto nitrocellulose or PVDF 
membranes. Membranes were incubated overnight with the primary antibodies followed by 
incubation with HRP-conjugated secondary antibodies (Amersham) and ECL substrate (Thermo 
Scientific™). 
Angiogenesis assay. The angiogenesis assay was performed using the in vitro angiogenesis 
kit (Cellworks #ZHA4000). In brief, human umbilical vein endothelial cells (HUVEC) were 
seeded in 24 multiwell plates and cultured for 14 days in the presence of conditioned media 
from neuroblastoma cells that was changed every 2 days. The endothelial cells were fixed with 
70% ethanol at room temperature for 30 minutes, incubated with anti-human anti-CD31 
antibody (1:400) for 1h at 370 C, followed by incubation with goat anti-mouse conjugated to 
alkaline phosphatase. To visualize the vascular structures, cells were stained using 5-bromo-4-
chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) at room temperature until tubules 
develop a dark purple colour, washed with distilled H2O and let to air dried. Images were 
captured using JuLI™ - Smart Fluorescent Cell Analyser and analysed using AngioSys 1.0 
Image Analysis Software (Cellworks #ZHA-1800). 
Constructs, transfection, retroviral/lentiviral infections. Human PML-I isoform and PML-IV 
isoform coding sequences were cloned into the pBabe puro and pBabe hygro retroviral vectors, 
respectively (9). shPML pLKO and pLKO scrambled lentiviral plasmids were a kind gift from the 
Everett’s lab (32). pGIPZ eGFP PML, TSP2 and pGIPZ eGFP scrambled plasmids were 
purchased from Open Biosystems/Dharmacon and lentiviral supernatants were prepared 
according to the manufacturer’s protocol (most efficient sequences were used for the study). 
The sequence of the shRNA (GIPZ Clone V3LHS_402844) used for TSP2 downregulation 
studies was TATATGTAAACGTCATTCT.  After infection the cells were cultured in presence of 
puromycin or hygromycin to select for infected cells. For pGIPZ eGFP lentiviral infection, 
infected GFP+ cells with the highest level of plasmid expression were selected using FACS 
sorting. Overexpression and downregulation of PML protein was confirmed by Western blot and 
fluorescent immunostaining. 
Antibodies. Rabbit anti-human pan PML (H238) (1:200 for Western blot and immunostaining, 
Santa Cruz, #SC-5621), mouse anti-human pan PML (PG-M3) (1:200 for immunostaining, 
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Santa Cruz, #SC-966), anti-mouse pan PML (1:100 for Western blot and immunostaining, 
Millipore, #05-718), rabbit anti-human PML-I (diluted 1/100; produced by Hugues De The), anti-
NCAM (1:400, Chemicon, #AB5032), anti-HIF1α (1:1000, BD Biosciences, #6109059), anti-
Sox10 (1:3000, produced in Michael Wegner’s lab, a kind gift from Huiliang Li, UCL), anti-
tyrosine hydroxylase (TH, 1:200, Millipore, #AB152), anti-p75 (1:250, Promega, #G3231), anti-
actin (1:5000, Sigma, #A2172), anti-CD31 (1:50, BD Pharmingen, #550274; for mouse tissue), 
anti-CD31, mouse monoclonal (diluted 1/100; Dako Cytomation, Hamburg, Germany; for human 
tissue).  
RNA extraction and quantitative real-time (qRT) PCR. Total RNA was extracted using 
RNAeasy Plus Mini Kit (Qiagen) and cDNA was synthesized using High Capacity RNA-to-cDNA 
Kit (Applied Biosystems) according to the manufacturer’s instructions. qRT PCR was performed 
in Applied Biosystems 7500 Real-Time PCR System thermo cycler using Maxima™ SYBR 
Green qPCR Master Mix (Fermentas). PML mRNA was normalised by measuring β-actin mRNA 
levels. The following primers were used:  
PML total sense 5’-GGTGCAGAGGATGAAGTGCT 
PML total antisense 5’-AGGAAACCGTGCATGTCC 
PML-I sense 5’-CTCAGGGTCCTGGACGAGAACC 
PML-I anti-sense 5’-CACGGCCTTGGAGTAGATGC 
β-actin sense 5’-CCAACCGCGAGAAGATGA 
β-actin 5’-TCCATCACGATGCCAGTG 
TSP2 sense 5’-CTTTAGCTGCTGCTTGTGCC 
TSP2 antisense 5’-GCGTTAGATGCGCCTTTTCC. 
In vivo experiments. Immunodeficient NOD/SCID female mice (purchased from Harlan; 
10/group) were subcutaneously injected into both flanks with 1x106 neuroblastoma cells. 
Tumour size was monitored with a calliper and calculated according to the formula: V=(length x 
width2)/2. Transgenic human-MycN TH mice (strain 129/SvJ) were kindly provided by Dr. Louis 
Chesler (Institute of Cancer Research, London, UK). Wild type C57BL/6 mice were obtained 
from the Jackson laboratories (via Charles River Laboratories). All experimental procedures 
involving wild type and transgenic mice were approved by the University College London and 
were conducted under the Animal Scientific Procedures Act, 1986 (United Kingdom). 
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Microarray. Total RNA was extracted from IMR32 pBpuro and PML-I-OE using Qiagen RNeasy 
Mini Kit 74104 (n=2). cDNAs labelled were prepared with SuperScript III RT kit (Invitrogen) 
using 5 µl of total RNA. Microarray slides were pre-hybridized in 3X SSC, 0.1% (w/v) SDS and 
10 mg/ml bovine serum albumin (BSA) at 600 C for 20 min. Following pre-hybridization, slides 
were washed with distilled water for 1 minute and isopropanol for 1 minute, dried with an 
airbrush and pre-scanned to check for any array defects.  
The capture sequence-tagged cDNAs were hybridized onto the microarray slide for 16 h at 550 
C in a SlideBooster SB400 (Advalytix) with the power setting at 27 and a pulse:pause ratio of 
3:7. The slides were washed in 2xSSC, 0.2% (w/v) SDS for 10 min at 550 C and then for 10 min 
at room temperature. The slides were dried and hybridized with the Cy3 and Cy5 dendrimers 
(3DNA 900, Genisphere) following manufacturer’s instructions. Dried slides were scanned using 
a Inno Scan 700 (Innopsys) using autocalibration to obtain optimized non-saturating images for 
each fluorophore and analysed using BlueFuse for Microarrays (BlueGnome).  
The data underwent Cross Channel Correction, followed by Lowess Normalisation. After 
normalising the data, the mean fold ratio value was derived and a cyber-T test was performed to 
generate a p-value. The software BASE was used to carry out the normalization. The data has 
been deposited in NCBI's Gene Expression Omnibus (33) and is accessible through GEO 
Series accession number GSE78086 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78086). 
Pathway Analysis. Oligos with a p-value below 0.05 (Cyber t-test) and a fold ratio ≥1.5 for up-
regulation or ≤0.67 for down-regulation were selected. This resulted in 1567 up-regulated and 
1195 down-regulated oligos, of which 1219 and 876, respectively, could be uniquely mapped to 
Entrez gene IDs (Supplementary Table 1). We then tested both sets of genes for enrichment of 
known pathways from various databases provided by ConsensusPathDB (34). Pathways with q-
value≤0.1 for ConsensusPathDB were considered significantly enriched (Supplementary Table 
2). 
Statistical analysis. Correlations were evaluated by the Spearman’s rank correlation coefficient 
(rS); rS values from 0.40 to 0.59 were considered moderate, from 0.60 to 0.79 were considered 
strong, and from 0.80 to 1 were considered very strong; values below 0.4 were considered 
weak. To compare quantitative variables between two groups of observations, the non-
parametric Mann-Whitney U test was used. Statistical significance of differences between 
experimental and control groups was determined by ANOVA with Tukey’s multiple comparison 
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test using GraphPad Prism 3.0 software (GraphPad Software, Inc.). Survival curves were 
constructed by using the Kaplan-Meier method. 
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Results 
We have previously shown that PML is expressed in neural progenitor/stem cells of the 
developing neocortex (9). In order to evaluate its expression during development of the 
peripheral nervous system, we performed immunohistochemical analysis of neural crest 
progenitors of the sympathetic nervous system and, postnatally, in the adrenal gland medulla. 
PML was found expressed in a subset of embryonic p75-positive progenitors delaminating from 
the neural tube and in TH-positive cells in the developing and adult adrenal medulla (Figure 1A). 
Similarly, in vitro cultures of neural tube-derived progenitors showed PML accumulating in a 
subset of p75- and Sox10-positive cells (Figure 1B). 
As neuroblastoma is believed to originate from progenitor cells of the developing sympathetic 
nervous system (20), we evaluated PML expression in neuroblastomas arising in tyrosine-
hydroxylase (TH)-MYCN-transgenic mice, and found that it was downregulated in most tumours 
analysed (Figure 1C). We next assessed the expression of PML in primary neuroblastoma 
patients at presentation by immunohistochemical or immunofluorescence analysis in two 
independent cohorts. We showed that PML expression is high in the adult human adrenal 
medulla, but it is generally low in neuroblastomas (Figure 1D; Supplementary Table 1, two 
separate cohorts). Notably, the cumulative survival probability of patients whose localised 
tumours contained more than 40% of PML positive cells was excellent, with 100% event free 
survival probability after 7 years from diagnosis (Figure 1E; Supplementary Table 1). In stark 
contrast, survival probability of patients whose tumours contained less than 40% PML positive 
cells was only 10% after 2 years (Figure 1E). There was a striking correlation between low 
expression (<40% positive cells) of PML and tumour recurrence in localised, low-risk, patients, 
suggesting that PML expression may represent an accurate biomarker of relapse 
(Supplementary Table 1). Using double-staining immunohistochemical analysis we also 
assessed a third and larger cohort (Supplementary Table 2) that included relapsed cases only 
for stage 3-4 tumours. It is important to note that in this cohort MYCN-amplified tumours 
displayed significantly higher PML expression than MYCN-non-amplified samples 
(Supplementary Table 2 and Supplementary Figure 1A). PML expression in MYCN-non-
amplified tumours (all stages) and MYCN-non-amplified stage 4 tumours was significantly 
associated with a reduced risk of tumour relapse (Supplementary Table 2 and Supplementary 
Figure 1B, C).  
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We next investigated PML expression in a panel of neuroblastoma cell lines. As mentioned 
above, there are several splice variants that produce seven or more protein isoforms, which 
retain a common tripartite motif but vary in their C-termini (12, 35). Analysis of total PML 
expression by Western Blotting and immunofluorescence analyses using a pan-PML antibody 
showed that a number of cell lines display low PML expression, with the most prominent PML 
isoform migrating at around 90-100 kilodalton (kDa), which corresponds to the PML-I (and PML-
II) isoforms (Figure 2A, B). The mRNA levels of PML-I generally correlate with the high-
molecular weight PML isoform (Figure 2C). Interestingly, PML-I expression seemed to be 
associated especially with Schwannian or intermixed types (Figure 2A-C). These findings 
suggest that there is, at least in part, a selective expression of PML isoforms in neuroblastoma 
cell lines. We then assessed the effect of reconstituting PML expression in PMLlow 
neuroblastoma cells. To this end, PMLlow IMR32 cells were infected with retroviral vectors 
expressing PML-I or the tumour-suppressive PML-IV isoform (Figure 2D) and analysed for their 
growth properties. PML-IV-, but not PML-I-expressing cells showed a marginal but significant 
inhibition of proliferation compared to vector-infected control cells (Figure 2E). The PML-
reconstituted cell lines were injected into the flanks of immunodeficient mice and tumour 
masses were measured at regular intervals for about 4 weeks. Experiments were terminated 
when the tumour size reached the upper limit allowed by UK and local animal welfare 
regulations. While neuroblastoma cells infected with the control or PML vectors formed tumours 
of comparable size, necroscopic and pathological analyses revealed that PML-I tumours were 
paler compared to control or PML-IV tumours (Figure 3A, B). Indeed, immunofluorescence 
analysis of the CD31 endothelial marker, revealed that there was a significant reduction in 
vascular clusters in PML-I compared to control tumours (Figure 3C). Furthermore, decreased 
angiogenesis in PML-I tumours correlated with enrichment in S100-positive Schwann-like cells, 
typically associated with low-risk forms of neuroblastoma (26, 27), and reduced number of cells 
expressing the neuroblast marker CD56 (Figure 3D). This effect did not appear related to a cell-
autonomous effect of PML-I on S100, as expression of this marker was not increased in PML-I-
overexpressing cells in vitro (not shown).  
These results prompted us to investigate whether PML-I-expressing cells secrete antiangiogenic 
factor(s) that could explain the observed phenotype. We used supernatants from PML-I or 
empty vector-infected IMR32 cells in endothelial cell tubule formation assays with human 
umbilical vascular endothelial chord (HUVEC) cells. We observed inhibition of tubule number, 
length and branching when HUVEC cells were exposed to the PML-I, but not control, 
supernatants (Figure 3E). These in vitro results were corroborated by immunofluorescence 
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analysis in neuroblastoma patients that confirmed that there was a statistically significant 
inverse correlation between CD31 positive microvessel clusters and PML expression (Figure 
3F, G and Table 1). Thus, PML regulates angiogenesis in vitro and in vivo.  
We next studied the potential mechanisms involved. Based on previous studies (36), the PML-
IV isoform controls angiogenesis via an mTOR/HIF1α/vascular endothelial growth factor (VEGF) 
axis in fibroblasts and prostate cancer. However, we failed to detect differences in HIF1α levels 
in either normoxic or hypoxic conditions (Supplementary Figure 2A), thus implicating different 
mechanisms underlying PML-I-mediated regulation of angiogenesis in neuroblastoma. 
Therefore, we set out to study the potential effect of PML-I on gene expression. We analysed 
gene expression in PML-I and pBabe control IMR32 cells using custom-made arrays. As 
expected, PML-I appears to modulate a number of genes involved in cell cycle control (see 
Pathway Analysis in Supplementary Table 3), but also some regulating angiogenesis (not 
VEGF). Among them, thrombospondin-2 [TSP2 (THBS2)], a known inhibitor of angiogenesis 
(37-39), displayed over 4-fold increased expression in PML-I-transduced cells (Supplementary 
Table 4). These findings were validated via quantitative PCR (QPCR) and Western Blotting 
(Figure 4A, B). A western blot confirming substantial overexpression of PML-I in neuroblastoma 
cells after retroviral infections is shown in Supplementary figure 2B. In order to define the 
involvement of TSP2 in PML-I-mediated suppression of angiogenesis, we transduced control or 
PML-I-expressing IMR32 cells with lentiviral vectors expressing TSP2-specific or control 
shRNAs (Figure 4C). Critically, while TSP2 knockdown in control cells did not affect 
angiogenesis, it rescued the suppressive phenotype caused by PML-I (Figure 4D). A western 
blot confirmed that the TSP2 shRNA did not change the levels of overexpressed PML-I in 
neuroblastoma cells (Supplementary Figure 2C). Finally, by using PML-I- and TSP-2-specific 
antibodies tissue sections from neuroblastoma patients were scored as the percentage of 
stained nuclear and cytoplasm respectively neuroblastoma cells (Figure 4E). We revealed a 
correlation between expression of PML-I and TSP-2 (Spearman’s correlation rank r=0.89), 
suggesting that the functional relationship is conserved in primary neuroblastoma (Table 2). 
Overall, our findings indicate that the tumour suppressor PML suppresses angiogenesis at 
multiple levels via the specialised functions of two of its splice forms, PML-I and PML-IV.  
 
Discussion 
Localised tumours without amplification of MYCN is a group of particular interest due to a 
difficult risk estimation resulting in quite different therapeutic options (intermediate-risk 
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chemotherapy versus wait-and-see strategy without chemotherapy) (40, 41). In this study, we 
have established that loss of PML expression identifies patients with localised disease at risk of 
tumour relapse that will potentially benefit from chemotherapeutic treatment, suggesting that 
PML could be used as a marker to guide therapeutic intervention. Interestingly, PML did not 
appear to act as a growth suppressor in neuroblastoma, as transduction of the growth 
suppressive PML-IV isoform in PMLlow neuroblastoma cells only marginally inhibited cell growth, 
whereas PML-I had no effect on either cell or tumour growth. In contrast, transduction of PML-I 
led to inhibition of angiogenesis both in vitro and in vivo. We cannot exclude that prolonged 
observation of tumour growth could have revealed differences in tumour size as well, but we 
could not extend the analysis due to animal welfare regulations. These data indicate an isoform-
specific PML role in regulation of angiogenesis in neuroblastoma. Notably, PML expression 
inversely correlated with tumour angiogenesis index in patient samples. More generally, these 
findings suggest a novel role for tumour angiogenesis in relapse of localized tumours.  
It is interesting to note that PML-IV was reported to inhibit angiogenesis via an mTOR/HIF1α-
dependent mechanism (36), but we failed to detect an angiogenesis role of PML-IV in 
neuroblastoma nor changes in HIF1α protein levels. Instead, PML-I appears to work as a 
HIF1α− angiogenesis suppressor via transcriptional regulation of 
thrombospondin-2 (TSP2), a known inhibitor of angiogenesis and tumourigenesis (37, 38, 42). 
Although it remains to be determined how PML-I could regulate TSP2, our findings suggest that 
a novel PML-I/TSP2 signalling module suppresses tumour angiogenesis in neuroblastoma. 
Considering the effect of PML-I expression on the retinoblastoma pathway (see Pathway 
Analysis and (9)), one could speculate that pRb/E2Fs regulates TSP2 gene expression. In this 
respect, as oncogenic RAS is known to inhibit the expression of TSP2 in tumour cells (43), it 
could be hypothesized that TSP2 induction could be part of a PML/pRb tumour suppressive 
checkpoint triggered by RAS activation in normal cells (44).  
Another finding of our study is the association between reduced angiogenesis and increased 
expression of Schwann-like markers in PML-I-overexpressing tumours. The presence of 
Schwann-like differentiation in neuroblastoma is a good prognostic marker and has been found 
associated with reduced angiogenesis (45), although it is still debated whether cells carrying 
Schwann markers with neuroblastoma tumours are of tumour origin (46, 47). A previous report 
suggested that PML expression correlates with the Schwann-like phenotype in cell lines and 
that reintroduction of PML in PMLlow Neuronal (N-type) cells induced neurite extension (48). 
However, we failed to observe a differentiation-promoting effect of PML in N-type IMR32 cells 
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nor increased expression of the Schwannian marker S100 in vitro. Thus, our study suggests 
that PML may regulate Schwannian differentiation within neuroblastoma tumours via 
angiogenesis inhibition or that TSP2 itself may have direct pro-differentiation properties in vivo. 
In keeping with this, TSP2 has been shown to induce synaptogenesis in the central nervous 
system (49) and chondrogenic differentiation in the bone (50).  
In conclusion, our study reveals a novel PML-I/TSP2 axis regulating neuroblastoma 
angiogenesis and differentiation, which could serve as biomarker to predict relapse in localized 
neuroblastoma. More generally, PML is emerging as key player in angiogenesis regulation via 
the ability of two of its splice forms, PML-I (the present study) and PML-IV (36) to control 
different steps of the angiogenesis process.  
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Figure legends 
 
Figure 1: PML expression is low in neuroblastoma compared with normal tissues and is a 
marker of high-risk tumours. (A) Immunofluorescence analysis of PML expression in 
sympathetic neurons during mouse development. PML is detectable in early neural crest p75+ 
progenitors in the neural tube, and in TH+ medullar cells in the developing and adult adrenal 
gland (scale bar 50m); (B) Expression of p75, Sox10 and PML in neural crest progenitors in 
vitro. (C) PML expression is low in neuroblastomas arising in TH-MycN transgenic mice. Upper 
panel: Western blot analysis showing PML expression (indicated by the arrows) in tumours (T1-
13) compared to normal adrenal gland (N). Equal loading was verified by blotting with an actin 
antibody (bottom gel). Lower panel; representative images of immunofluorescence analysis 
showing co-expression of PML and the neuroblast marker NCAM (numbers indicate tumours 
ID). (D) Immunohistochemical analysis demonstrating co-expression of PML in primary human 
neuroblastomas compared to normal adrenal gland. An anti N-CAM antibody was used to mark 
neuroblastic tumour cells (E) Low PML expression in localized human neuroblastomas is 
associated with increased probability of relapse (p<0.0001, Mann-Whitney test) and reduced 
cumulative survival probability (p<0.0001, log-rank test); immunofluorescence analysis of 
tumours from three patients is shown on the left.  
 
Figure 2: Expression of PML isoforms in neuroblastoma cell lines and effect on cell 
growth. (A) Western blot analysis showing expression of total PML in neuroblastoma cell lines. 
Actin was used as loading control. Quantification of the western blot analysis is shown in the 
bottom. (B) Immunofluorescence analysis of total PML expression in neuroblastoma cell lines. 
(C) Reverse transcription Q-PCR analysis was used to assess the relative expression of total 
PML and the PML-I isoform in neuroblastoma cell lines. Primary glioblastoma neural stem cells 
(G4) and foetal neural stem cells (NSC) were used as negative and positive controls, 
respectively. The bars indicate the mean values from triplicate wells and the error bars standard 
errors. (D) Western blot analysis showing exogenous overexpression of the PML-I and IV 
isoforms in IMR32 cells. (E) Proliferation curves showing the growth rates of IMR32 cells 
transduced with an empty retroviral vector or viruses containing the PML-I and PML-IV isoforms, 
as indicated. Points in the curve are the mean values from triplicate wells and the error bars 
indicate standard errors.  
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Figure 3. PML-I inhibits angiogenesis in human neuroblastomas. (A, B) IMR32 cells 
expressing (PML-I-OE and PML-IV-OE) or non expressing (pBpuro and pBhygo) PML isoforms 
were injected into the flanks of immunodeficient mice. At the end of the experiment, tumours 
were excised and photographed (A panel). Tumour volumes were also measured every other 
day starting from one week after injections of neuroblastoma cells (B panel). Values represents 
means +/- SD, n=10 for PML-I/PML-IV and vector controls; stars refer to individual time points at 
which p-values were calculated, albeit not significant (t-test). C) CD31+ vascular clusters 
(indicated by the arrows) were detected in the xenotransplanted tumour using 
immunofluorescence analysis (left panels). Quantification of the experiment is shown in the right 
panel (*** = P<0.001). (D) Immunohistochemical analysis of representative sections of control 
(pBpuro) or PML-I overexpressing (PML-I-OE) tumour xenografts. The antibodies used are 
indicated (H&E=haematoxylin and eosin). (E) Angiogenesis assay. The upper panel shows 
images of the vascular structures in the presence of pro- (VEGF), anti- (Suramin) angiogenic 
factors or supernatants from cells expressing (PML-I OE) or non expressing (pBpuro) PML-I. 
Quantification of the experiment is shown in the bottom panel. Bars indicate the means of 
triplicate values and error bars the standard errors. (F) Microvessel clusters (red) in primary 
human neuroblastomas were detected by immunofluorescence analysis using a CD31 antibody; 
nuclei were counter stained with DAPI (blue). Scale bar = 32 μm.  Representative image 
showing a tumour with high MCV/low PML (left) and a tumour with low MCV/high PML (right). 
(G) Graph showing a reverse correlation between the number of CD31+ micro-vessel clusters 
and PML positive cells in the whole tumour area (Spearman’s correlation rank r=-0.89).  
 
Figure 4. PML-I induces expression of Thrombospondin 2 (TSP2), which is required for 
the antiangiogenic activity. (A) Reverse transcription Q-PCR analysis confirming 
overexpression of TSP2 in PML-I expressing cells (PML-I-OE) relative to control (pBpuro); the 
bars indicate the mean values of three independent experiments and error bars standard errors. 
(B) Western blot analysis showing increased expression of TSP2 protein in PML-I-expressing 
cells. Quantification of the western blot is shown in the right panel. (C) Western blot assay 
showing reduced expression of TSP2 in neuroblastoma cells transduced with a TSP2 shRNA 
with (PML-I-OE Sh) or without (pBpuro Sh) PML-I overexpression. It should be noted that PML-I 
overexpression (PML-I-OE) caused up regulation of TSP2 with respect to control cells (pBpuro). 
Quantification of the western blot is shown on the right.  (D) Angiogenesis assay. The reduction 
in angiogenesis caused by incubation of HUVEC cells with supernatants from neuroblastoma 
cells overexpressing PML-I (PML-I-OE) was reverted by knockdown of TSP2 (PML-I-OE Sh). 
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Bars indicate the mean values of four independent experiments and error bars the standard 
errors. Representative images from the Angiogenesis assay are shown in the top of the panel. 
(E) Immunofluorescence analysis showing co-expression of PML-I and TSP2 in sections of 
primary human neuroblastomas.  Statistical analysis shows a significant degree of correlation 
(Spearman’s correlation rank r=0.89).  
 
Table 1. Correlation of PML expression with tumor microvessel density in localised and 
metastatic tumors. 
 
Table 2. Analysis of total PML, PML-I and TSP2 expression in localised and metastatic tumor 
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